Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

386190

registered interest
date	29/06/2015
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	Developing Countries: Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Development, what assessment she has made of the efficacy of the research and development pipeline for diagnostics, drugs and vaccines for poverty-related and other neglected diseases.
tabling member constituency	Oxford East
tabling member printed	Mr Andrew Smith
uin	4502
answer	answer is ministerial correction date of answer 06/07/2015 answer text <p>Historically there has been a lack of investment in the development of diagnostics, drugs and vaccines for poverty-related and other neglected diseases. In the last 15 years increasing investments in research have resulted in over 200 products at various stages of development. A large part of this increase has been due to the establishment of a number of public-private product development partnerships (PDPs) developing a range of technologies for a number of different diseases.</p><p> </p><p> </p><p>PDPs aim is to accelerate the development of new products and to date they have developed over twenty new products. It has been estimated that there is around a 10% return on investment per annum from medical research. There is insufficient funding available to support the development of all the promising products currently in PDP portfolios and DFID works in partnership with others to encourage greater investment.</p> answering member constituency Welwyn Hatfield answering member printed Grant Shapps question first answered 06/07/2015 16:04:36 answering member 1582 label Biography information for Grant Shapps
tabling member	95 label Biography information for Mr Andrew Smith

386191

registered interest
date	29/06/2015
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	Developing Countries: Tropical Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Development, what assessment her Department has made of the effect of the patenting of new drugs on their price and availability to treat neglected tropical diseases overseas.
tabling member constituency	Glasgow North
tabling member printed	Patrick Grady
uin	4494
answer	answer is ministerial correction date of answer 02/07/2015 answer text <p>Most drugs required to treat Neglected Tropical Diseases (NTDs) are donated free of charge by pharmaceutical companies. However, in some cases the drugs need to be purchased. In these cases we work to secure good value for money in our procurement and also encourage flexible approaches to increase availability, such as licensing and technology transfer partnerships with low-cost, high-quality generic manufacturers.</p><p> </p><p> </p><p>DFID also funds research into new NTD treatments through Product Development Partnerships (PDPs). PDPs use patents flexibly to ensure products are available at lowest possible cost. This includes negotiating royalty-free access to patented products and developing products as ‘open source’ so that anyone can use them, with requirements for distribution at the lowest possible cost. PDPs can also patent new products at an early stage and then use the patent to attract partners to help develop the products and make them available at the lowest possible cost.</p> answering member constituency Welwyn Hatfield answering member printed Grant Shapps question first answered 02/07/2015 16:22:48 answering member 1582 label Biography information for Grant Shapps
tabling member	4432 label Biography information for Patrick Grady